en · de · es · fr · pt
tb-500-notes.peptides5388.com › Info › Tb-500 Identity And Naming Background — Research Overview

Tb-500 Identity And Naming Background — Research Overview

By Editorial Desk · published 2025-12-22 · last reviewed 2026-01-13 · Info

If you have been reading about actin binding and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.

Last reviewed on 2026-01-13. Where a claim depends on a specific study, the study is described rather than over-claimed.

TB-500 Identity and Naming Background

Thymosin beta-4 itself is a natural peptide of 43 residues found in many cell types and body fluids. Its best-characterised function is binding and sequestering actin monomers, which influences cytoskeletal dynamics. The sequence most often associated with TB-500, LKKTETQ, corresponds to part of that actin-binding region. A different fragment, Ac-SDKP, is also derived from the same parent peptide and is studied in its own right, which is one reason discussions of thymosin fragments can become confusing. The two are structurally distinct and are not interchangeable.

Interest in the fragment grew during the 1990s and 2000s, when it moved from laboratory work into sports and supplement markets. Anti-doping bodies added thymosin beta-4 fragments to prohibited lists, and a small number of adverse analytical findings have been reported in competition testing. Published controlled human trials remain scarce. Most mechanistic evidence comes from cell culture and animal models, and those studies examine endpoints such as cell migration, wound closure and inflammation markers. That evidence supports research interest but does not establish clinical benefit, and broad regenerative claims should be read as unverified.

TB-500 Identity and Molecular Background

Regulatory status differs by country, but TB-500 is not an approved pharmaceutical in major jurisdictions. It is commonly sold as a research chemical for laboratory use, which places responsibility for identity and purity on the supplier and the laboratory. Published human data are limited, and most reports involve preclinical models or cell culture. Questions about whether the fragment mimics all actions of thymosin beta-4, and under which conditions, remain open. Independent verification of any material is therefore a practical requirement in research settings.

TB-500 is a synthetic heptapeptide with the sequence Ac-LKKTETQ. It corresponds to a short N-terminal region of thymosin beta-4, a 43-amino-acid protein found in many cell types. The fragment contains an actin-binding motif, which is one reason it appears in laboratory studies of cell migration and cytoskeletal dynamics. TB-500 is not the full-length protein and is produced as a research chemical rather than an approved therapeutic agent. Its molecular weight is approximately 889 Da.

Tb-500 at a glance

PropertyValueNotes
Name typeCommercial trade nameNot a systematic chemical identifier
Parent peptideThymosin beta-443-residue natural peptide
Common fragment sequenceLKKTETQMaps to part of the actin-binding region
Molecular size classRoughly 0.8-1.0 kDaDepends on exact fragment and terminal modification
Regulatory statusProhibited in sportGrouped with peptide hormones in many frameworks

Identity and Research Background

Thymosin beta-4 is a 43-residue actin-binding protein found in most mammalian cell types, where it participates in cytoskeletal regulation and cell migration. TB-500 represents only a short fragment of that protein and does not include the remaining residues. Whether the isolated fragment reproduces the full range of activities reported for the intact protein remains an open question. Researchers commonly treat the two as related but distinct entities when comparing results.

Published work involving this sequence spans actin-binding assays, cell-migration studies, wound-healing models, and cardiovascular or musculoskeletal experiments. Much of the biological rationale derives from in vitro systems and animal models, and the number of controlled human studies is small. Reported outcomes vary across preparations, doses, and routes, which complicates comparison between studies. Reviews generally describe the evidence base as preliminary rather than settled. Mechanistic explanations are often proposed by analogy to the parent protein rather than demonstrated directly.

Related pages on this site

Thymosin Beta-4 Fragment Overview

TB-500 refers to a synthetic peptide fragment derived from the actin-binding region of thymosin beta-4, a protein present in most mammalian cells. The full protein contains forty-three amino acids, while the commonly sold fragment is a much shorter acetylated sequence, often cited as LKKTETQ. The fragment retains part of the actin-binding motif but lacks the remainder of the parent protein. Material sold under this name is usually lyophilized powder intended for laboratory research, and it is not a finished pharmaceutical product.

Proposed activity centers on actin sequestration and on the movement of cells during repair processes. In cell culture and animal models, the fragment has been associated with migration, tube formation, and tissue remodeling. These observations are frequently described as preliminary, because most published work uses rodent or in vitro systems rather than controlled human trials. Whether the short fragment reproduces the effects of the full protein remains an open question, and the relationship between dose, route, and measured outcome is not well characterized.

Identity and Physical Form

The fragment most often associated with the name carries the sequence Ac-LKKTETQ, matching residues 17 through 23 of thymosin beta-4. That region holds the actin-binding motif responsible for much of the parent protein's biochemical activity. Apart from N-terminal acetylation the peptide is unmodified and contains no disulfide bonds, so it shows little ordered secondary structure in solution. Full-length thymosin beta-4 is instead a 43-residue polypeptide of roughly 4.9 kDa found widely across mammalian cell types.

Material sold under this label typically arrives as a freeze-dried powder in a sealed vial with a certificate of analysis. Such certificates usually report reversed-phase chromatography purity plus a mass confirmation, and stated purities commonly sit between 95 and 99 percent. Counter-ion identity, residual trifluoroacetate, water content, and peptide net weight are separate specifications that a certificate may or may not include. A purity figure alone does not establish sequence identity, so independent mass verification remains the practical check.

The designation TB-500 circulates in laboratory and catalog contexts without a single agreed definition. Most product listings apply it to an N-terminally acetylated seven-residue fragment of thymosin beta-4, while other listings attach the same label to the full 43-residue protein. Because the term is commercial rather than systematic, two entries bearing identical names may describe different molecules. Any documentation should therefore state which sequence a given sample is claimed to contain.

Further detail

ADAM (A Database of Anti-Microbial peptides) Archived 2015-06-17 at the Wayback Machine at ntou.edu.tw AntiFP Prediction of antifungal peptides AntiMPmod Prediction of antimicrobial potential of modified peptides Antimicrobial+Cationic+Peptides at the U.S. National Library of Medicine Medical Subject Headings (MeSH) AntiTbPred Prediction of anti-tuberculosis peptides Antimicrobial Peptide Database Archived 2011-07-20 at the Wayback Machine at University of Nebraska Medical Center Antimicrobial Peptide Scanner Deep Learning based AMP prediction server AntiTbPdb Anti Tubercular Peptide Database BioPD[link removed] at Peking University Health Science Center CAMP:Collection of Anti-Microbial Peptides at National Institute for Research in Reproductive Health (NIRRH) DBAASP - Database of Antimicrobial Activity and Structure of Peptides] LAMP at Fudan University PeptideLocator Prediction of functional peptides, including antimicrobial peptides, in a protein sequence PeptideRanker Bioactive peptide, including antimicrobial peptide, prediction modlAMP Python package for computational work with antimicrobial peptides, including sequence handling, -design, -prediction, descriptor calculation and plotting

Human chorionic gonadotropin is a glycoprotein composed of 237 amino acids with a molecular mass of 36.7 kDa, approximately 14.5kDa αhCG and 22.2kDa βhCG. It is heterodimeric, with an α (alpha) subunit identical to that of luteinizing hormone (LH), follicle-stimulating hormone (FSH), thyroid-stimulating hormone (TSH), and a β (beta) subunit that is unique to hCG. The α (alpha) subunit is 92 amino acids long. The β-subunit of hCG gonadotropin (beta-hCG) contains 145 amino acids, encoded by six highly homologous genes that are arranged in tandem and inverted pairs on chromosome 19q13.3 - CGB (1, 2, 3, 5, 7, 8). It is known that CGB7 has a sequence slightly different from that of the others. The two subunits create a small hydrophobic core surrounded by a high surface area-to-volume ratio: 2.8 times that of a sphere. The vast majority of the outer amino acids are hydrophilic. beta-hCG is mostly similar to beta-LH, with the exception of a Carboxy Terminus Peptide (beta-CTP) containing four glycosylated serine residues that is responsible for hCG's longer half-life.

A common pathological cause for a high BMR is fever, since a rise in body temperature increases the rate of cellular metabolic reactions. It is estimated that for every degree Fahrenheit of rise in body temperature, the BMR increases by 7 percent. Thyroid disease also has a marked effect on BMR, since thyroid hormones regulate the rate of cellular metabolism. Hyperthyroidism—in which there is an increase in the production of thyroid hormones—leads to a high BMR, while hypothyroidism—in which thyroid hormones are depleted—causes a low BMR. Prolonged periods of abnormal nutrition cause an adaptive change in BMR; this helps the body to maintain a stable body weight in response to the change in food supply. In prolonged malnutrition, the BMR declines, while in prolonged overnutrition, the BMR is increased. Cancer sometimes causes an increase in BMR, perhaps because the cancer cells that form tumors have a high level of metabolic activity.

Traditionally, Escherichia coli is the choice bacterium to express eukaryotic and recombinant genes. E. coli is well understood and has a successful track record producing insulin, the artemisinin precursor artemisinic acid, and filgrastim (Neupogen). However, use of E. coli has limitations including misfolding of eukaryotic proteins, insolubility issues, deposition in inclusion bodies, low secretion efficiency, secretion to periplasmic space. Streptomyces offers potential advantages including superior secretion mechanisms, higher yields, a simpler end-product purification process, making Streptomyces an attractive alternative to E. coli and Bacillus subtilis. Streptomyces coelicolor, Streptomyces avermitilis, Streptomyces griseus, and Saccharopolyspora erythraea, are capable of secondary metabolite production. Streptomyces coelicolor has shown useful for the heterologous expression of proteins. Methods like "ribosome engineering" have been used to achieve 180-fold higher yields with S. coelicolor.

== History == Three scientists were involved in the discovery of lutetium: French scientist Georges Urbain, Austrian mineralogist Baron Carl Auer von Welsbach, and American chemist Charles James. They found lutetium as an impurity in ytterbia, which was thought by Swiss chemist Jean Charles Galissard de Marignac to consist entirely of ytterbium. Of the three, Urbain was the first to publish, followed by Welsbach; James was about to publish when he learned of Urbain's work, and thereafter gave up his claim and did not publish. Despite staying out of the priority argument, James worked on a much larger scale and possessed the largest supply of lutetium at the time. Urbain and Welsbach proposed different names. Urbain chose neoytterbium for ytterbium and lutecium for the new element. Welsbach chose aldebaranium and cassiopeium (after Aldebaran and Cassiopeia). Both authors accused the other man of publishing results based on their work. The International Commission on Atomic Weights, which was then responsible for the attribution of new element names, settled the dispute in 1909 by granting priority to Urbain and adopting his choice for a name, one derived from the Latin Lutetia (Paris). This decision was based on the fact that the separation of lutetium from Marignac's ytterbium was first described by Urbain. Welsbach had achieved the separation before Urbain, but Urbain had published 44 days earlier.

Sources: en.wikipedia.org

Supporting material

14 September NASA releases its first public study on UAP (also known as UFOs), and appoints Mark McInerney as the first Director of UAP, to scientifically and transparently study further such occurrences. A new record time for quantum coherence is reported, with a single-photon qubit encoded in a novel superconducting cavity for 34 milliseconds. A genetically engineered marine microorganism is shown to break down polyethylene terephthalate in salt water. This plastic, used in everything from water bottles to clothing, is a significant contributor to microplastic pollution in oceans. A study finds that rivers are warming and losing oxygen faster than oceans. Of nearly 800 rivers, warming occurred in 87% and oxygen loss occurred in 70%. The study projects that within 70 years, river systems could "induce acute death" and extinctions of aquatic species due to long low oxygen levels. Astronomers report studies related to the Hubble tension, a disagreement in results attempting to measure the Hubble constant, and find that the results from the James Webb Space Telescope support earlier results from the Hubble Space Telescope. According to astronomer Adam Riess, "With Webb confirming the measurements from Hubble, the Webb measurements provide the strongest evidence yet that systematic errors in Hubble's Cepheid photometry do not play a significant role in the present Hubble tension ...

As of 2024, the United Nations reports Ghana has a population of 34,581,288. As of 2018, around 29% of the population is under the age of 15, while persons aged 15–64 make up 57.8% of the population. The 2010 census reported that the largest ethnic groups are the Akan (47.3%), the Mole-Dagbani (18.5%), the Ewe (13.9%), the Ga-Dangme (7.4%), the Gurma (5.7%) and the Guan (3.7%). As of 2024, the United Nations reports the median age of Ghanaian citizens is 21 years old. Ghana contributes 0.42% to the total world population. With legal immigration of skilled workers who possess Ghana Cards, there is an increasing population of Chinese, Malaysian, Indian, Middle Eastern, American and European nationals and their descendants born in Ghana. In 2010, the Ghana Immigration Service reported economic migrants and undocumented immigrants inhabiting Ghana: 14.6% (or 3.1 million) of Ghana's 2010 population (mostly Nigerians, Burkinabe citizens, Togolese citizens, and Malian citizens). In 1969, under the "Ghana Aliens Compliance Order" enacted by then Prime Minister Kofi Abrefa Busia, the Border Guard Unit deported more than 3,000,000 aliens and undocumented immigrants in three months as they made up 20% of the population at the time. In 2013, there was a mass deportation of undocumented miners, more than 4,000 of whom were Chinese nationals.

Musca domestica (housefly) Fannia spp. (latrine flies) Eristalis tenax (rat-tailed maggots) Muscina spp. The adult flies are not parasitic, but when they lay their eggs in open wounds and these hatch into their larval stage (also known as maggots or grubs), the larvae feed on live or necrotic tissue, causing myiasis to develop. They may also be ingested or enter through other body apertures.

The Tomorrow People (1970's TV Series), featured plot lines reflecting Cold War tension between the desire of British and Soviet militaries to use the Tomorrow People's fictional "special powers" of telepathy, teleportation, and telekinesis.

Sources: en.wikipedia.org

Frequently asked questions

Is TB-500 the same as thymosin beta-4?

No. Thymosin beta-4 is a 43-residue natural peptide, while TB-500 is a commercial label applied to a short synthetic fragment of it. The two differ in length, sequence coverage and how they are handled in the laboratory.

What does research on the fragment actually measure?

Published work usually examines actin binding, cell migration and tissue repair endpoints in cell and animal models. Findings are generally described as preliminary, and controlled human data remain limited.

Why does the name cause confusion?

Because TB-500 is a trade name rather than a chemical identifier, different vendors and papers may attach it to different fragment lengths. Checking the stated sequence is the practical way to resolve the ambiguity.

What is TB-500?

TB-500 is a synthetic heptapeptide corresponding to a fragment of thymosin beta-4. It is used in laboratory research and is not an approved drug.

Network